30 Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wilk A, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54(9):12326. doi: 10.1136/gut.2004.060228. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004;99(11):2235-41. doi: 10.1111/j.15720241.2004.40369.x. van Schaik FD, Oldenburg B, Hart AR, Siersema PD, Lindgren S, Grip O, et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 2013;62(5):683-8. doi: 10.1136/ gutjnl-2012-302717. Choung RS, Princen F, Stockfisch TP, Torres J, Maue AC, Porter CK, et al. Serologic microbial associated markers can predict Crohn’s disease behaviour years before disease diagnosis. Aliment Pharmacol Ther 2016;43(12):1300-10. doi: 10.1111/apt.13641. Lee SH, TurpinW, Espin-Garcia O, Raygoza Garay JA, Smith MI, Leibovitzh H, et al. Anti-Microbial Antibody Response is Associated With Future Onset of Crohn’s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. Gastroenterology 2021;161(5):1540-1551. doi: 10.1053/j.gastro.2021.07.009. Colombel JF, Narula N, Peyrin-Biroulet L. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology 2017;152(2):351-361.e5. doi: 10.1053/j. gastro.2016.09.046. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99(1):91-6. doi: 10.1046/j.1572-0241.2003.04010.x. Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, crosssectional imaging and biomarkers in Crohn’s disease monitoring. Gut 2013;62(12):1806-16. doi: 10.1136/ gutjnl-2012-303957. Minderhoud IM, Steyerberg EW, van Bodegraven AA, van der Woude CJ, Hommes DW, Dijkstra G, et al. Predicting Endoscopic Disease Activity in Crohn’s Disease: A New and Validated Noninvasive Disease Activity Index (The Utrecht Activity Index). Inflamm Bowel Dis 2015;21(10):2453-9. doi: 10.1097/ MIB.0000000000000507. Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2008;6(11):1218-24. doi: 10.1016/j.cgh.2008.06.010. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140(6):1817-1826.e2. doi: 10.1053/j.gastro.2010.11.058. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008;103(1):162-9. doi: 10.1111/j.1572-0241.2007.01556.x. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55(3):426-31. doi: 10.1136/gut.2005.069476. Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A, et al. Comparison of 4 neutrophilderived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005;11(12):1085-91. doi: 10.1097/01.mib.0000187980.08686.18. 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Chapter 1
RkJQdWJsaXNoZXIy MjY0ODMw